NRG Oncology's GU007 (NADIR): A randomized phase II trial of niraparib with standard combination androgen deprivation therapy (ADT) and radiotherapy (RT) in high-risk prostate cancer (PC) (with initial phase I)

被引：4
|
作者：
Zumsteg, Z. [1 ]
Karrison, T. [2 ]
Michaelson, M. D. [3 ]
Tran, P. [4 ]
Kudchadker, R. [5 ]
Feng, F. [6 ]
机构：
[1] Cedars Sinai Med Ctr, Dept Radiat Oncol, Los Angeles, CA 90048 USA
[2] Univ Chicago, Dept Publ Hlth Sci, Chicago, IL 60637 USA
[3] Harvard Med Sch, Dept Med Oncol, Massachusetts Gen Hosp, Boston, MA 02115 USA
[4] Johns Hopkins, Dept Radiat Oncol, Baltimore, MD USA
[5] MD Anderson, Dept Radiat Oncol, Houston, TX USA
[6] Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA USA
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.2083
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
689TiP
引用
收藏
页码：S546 / S546
页数：1
相关论文
共 50 条
  • [31] Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 Trial (vol 37, pg 1159, 2019)
    Rosenthal, Seth A.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (17) : 1949 - 1949
  • [32] Phase I Study of Concurrent Weekly Docetaxel, Androgen Deprivation, and High-dose External Beam Radiation Therapy (RT) for High-risk Prostate Cancer
    Rosenman, J. G.
    Chen, R. C.
    Hoffman, L. G.
    Chiu, W. K.
    Pruthi, R. S.
    Wallen, E. M.
    Kim, W. Y.
    Rathmell, W. K.
    Godley, P. A.
    Whang, Y. E.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 78 (03): : S126 - S126
  • [33] A single arm, phase I/II trial of neoadjuvant androgen deprivation, darolutamide, and ipatasertib in men with localized, high-risk prostate cancer.
    Vander Weele, David James
    Fenton, Sarah Elizabeth
    Auffenberg, Gregory
    Jovanovic, Borko
    Hussain, Maha H. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [34] Phase II Trial of Enzalutamide and Androgen Deprivation Therapy with Salvage Radiation in Men with High-risk Prostate-specific Antigen Recurrent Prostate Cancer: The STREAM Trial
    Bitting, Rhonda L.
    Healy, Patrick
    George, Daniel J.
    Anand, Monika
    Kim, Sung
    Mayer, Tina
    Winters, Carol
    Riggan, Colleen
    Rasmussen, Julia
    Wilder, Rhonda
    Stein, Mark
    Frizzell, Bart
    Harrison, Michael R.
    Zhang, Tian
    Lee, William R.
    Wu, Yuan
    Koontz, Bridget F.
    Armstrong, Andrew J.
    EUROPEAN UROLOGY ONCOLOGY, 2021, 4 (06): : 948 - 954
  • [35] Radiotherapy with or without short term androgen deprivation therapy in intermediate risk prostate cancer: final results of a phase III randomized trial
    Nabid, Abdenour
    Carrier, Nathalie
    Vigneault, Eric
    Thu Van Nguyen
    Vavassis, Peter
    Brassard, Marc-Andre
    Bahoric, Boris
    Archambault, Robert
    Vincent, Francois
    Bettahar, Redouane
    Wilke, Derek
    Souhami, Luis
    SCANDINAVIAN JOURNAL OF UROLOGY, 2019, 53 : 8 - 8
  • [36] Randomised phase 3 trial of enzalutamide in androgen deprivation therapy (ADT) with radiation therapy for clinically localised high-risk or node-positive prostate cancer: ENZARAD (ANZUP 1303).
    Williams, Scott G.
    Davis, Ian D.
    Sweeney, Christopher
    Stockler, Martin R.
    Martin, Andrew James
    Hague, Wendy
    Coskinas, Xanthi
    Yip, Sonia
    Tu, Emily
    Chan, Howard
    Lawrence, Nicola Jane
    McDermott, Ray
    Hughes, Simon
    Marchesin, Vittorio
    Deignan, Olwyn
    Nguyen, Paul L.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [37] Phase I study of concurrent weekly docetaxel, high-dose intensity-modulated radiation therapy (IMRT) and androgen-deprivation therapy (ADT) for high-risk prostate cancer
    Chen, Ronald C.
    Rosenman, Julian G.
    Hoffman, Leroy G.
    Chiu, Wing-Keung
    Wang, Andrew Z.
    Pruthi, Raj S.
    Wallen, Eric M.
    Crane, Jeffrey M.
    Kim, William Y.
    Rathmell, W. Kimryn
    Godley, Paul A.
    Whang, Young E.
    BJU INTERNATIONAL, 2012, 110 (11B) : E721 - E726
  • [38] Results of a phase II trial of docetaxel (DOC), bevacizumab (BEV), and androgen deprivation therapy (ADT) for biochemical relapse (BCR) after definitive local therapy for prostate cancer (PC)
    Mckay, Rana R.
    Gray, Kathryn P.
    Hayes, Julia H.
    Bubley, Glenn J.
    Rosenberg, Jonathan E.
    Kantoff, Philip W.
    Taplin, Mary-Ellen
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [39] Randomized phase II trial of presurgical androgen deprivation therapy (ADT) with or without axitinib in prostate cancer (PCa) presenting with lymph node (LN) metastasis.
    Zurita, Amado J.
    Tidwell, Rebecca Slack
    Troncoso, Patricia
    Chapin, Brian Francis
    Harris, Deborah
    Pisters, Louis L.
    Araujo, John C.
    Pettaway, Curtis Alvin
    Aparicio, Ana
    Tu, Shi-Ming
    Papadopoulos, John N.
    Wang, Jennifer
    Logothetis, Christopher
    Pagliaro, Lance C.
    Davis, John W.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [40] Randomised phase 3 trial of enzalutamide in androgen deprivation therapy (ADT) with radiation therapy for high risk, clinically localized prostate cancer: ENZARAD (ANZUP 1303).
    Williams, Scott
    Davis, Ian D.
    Sweeney, Christopher
    Stockler, Martin R.
    Martin, Andrew James
    Hague, Wendy
    Coskinas, Xanthi
    Yip, Sonia
    Tu, Emily
    Lawrence, Nicola Jane
    Nayar, Namrata
    McDermott, Ray
    Kelly, Paul
    Deignan, Olwyn
    Hughes, Simon
    Fonteyne, Valerie
    Tombal, Bertrand F.
    Nguyen, Paul L.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
12345